Anzeige
Mehr »
Mittwoch, 15.07.2026 - Börsentäglich über 12.000 News
Warum sollte ein $1-Mrd.-Uranriese 15,6 % an einem Explorer zu 0,10 CAD kaufen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H5F4 | ISIN: FI4000252127 | Ticker-Symbol: 4TS
Frankfurt
15.07.26 | 09:10
7,460 Euro
-1,06 % -0,080
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
TERVEYSTALO OYJ Chart 1 Jahr
5-Tage-Chart
TERVEYSTALO OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
6,9907,17016:54
GlobeNewswire (Europe)
31 Leser
Artikel bewerten:
(0)

Terveystalo Oyj: Inside information, profit warning: Terveystalo lowers its guidance for 2026

Terveystalo Plc, Inside information, 15 July 2026 at 15:30 EEST

Terveystalo Plc lowers its guidance for 2026. The lowered guidance reflects the challenging demand environment in the first half of the year and profitability remaining below the level of the comparison period.

The demand environment in the first half of the year was very weak, which had a broad impact on the utilisation of services. In particular, in occupational health, volume development was negatively affected by a decrease in the number of connected employees compared to the comparison period, lower prevalence of upper respiratory infections, as well as cautious behaviour by corporate customers in an uncertain economic environment. Rare oversupply of resources in the industry has intensified price competition, which in turn has slowed new customer acquisition in occupational health and lowered the pricing level of new contracts. Weak demand development has been reflected across several businesses. However, early signs of stabilisation were seen in the market during the second quarter, particularly in consumer-driven services.

Guidance for 2026

Terveystalo expects its full-year 2026 adjusted operating profit (EBIT) to be EUR 120-140 million (2025: EUR 156.3 million).

Profitability in the first half of the year was clearly below the level of the corresponding period in 2025, and the demand environment was challenging. While the demand environment is still expected to gradually improve and the prevalence of upper respiratory infections is anticipated to return to long-term average levels during the second half of the year, the recovery in revenue and profitability is expected to lag the improvement in demand and therefore not fully materialise within the current year.

Revenue from outsourcing operations in the Portfolio Businesses segment is expected to decrease by approximately EUR 20 million due to expiring contracts. These estimates do not include the Hohde transaction, the acquisition of Silmäasema or any other significant acquisitions or divestments.

Guidance for 2026 provided in the Financial Statements Release on 13 February 2026:

Terveystalo expects its full-year 2026 adjusted EBIT to be EUR 135-165 million (2025: EUR 156.3 million).

The estimates are based on a gradually improving demand environment. The prevalence of upper respiratory infections is expected to remain low during the first half of the year and return to the long-term average in the second half. Profitability in the first half of 2026 is expected to be below that in the first half of 2025. Revenue from the Portfolio Businesses segment's outsourcing operations is projected to decrease by approximately EUR 20 million due to expiring contracts. These estimates do not include the Hohde transaction or any other significant acquisitions or divestments.

Preliminary information on Q2 2026

Terveystalo will publish its Half-Year Report for January-June 2026 on 17 July 2026.

Based on unaudited preliminary results, revenue for the second quarter of 2026 was approximately EUR 293.3 (321.5) million and adjusted operating profit (EBIT) was approximately EUR 26.1 (36.7) million, corresponding to approximately 8.9% (11.4%) of revenue.

Further information
CFO Juuso Pajunen
Tel. +358 40 584 9722

Terveystalo in brief

Terveystalo is the largest private healthcare service provider in Finland in terms of revenue and one of the leading occupational health providers in both Finland and Sweden.

We aim to create seamless, compassionate, and effective healthcare of the future. We offer comprehensive primary care, specialised care, and well-being services for corporate clients, insurance companies, consumers and public-sector customers. Terveystalo's digital appointments are available anytime, anywhere, 24/7. The Terveystalo app has around 2.7 million registered users. We provide services through our extensive network of clinics and hospitals across Finland. In Sweden, we offer preventive occupational health services through our subsidiary, Feelgood.

In 2025, Terveystalo served approximately 1.2 million individual customers, and there were around 7.2 million customer visits in Finland. Terveystalo employs around 14,400 professionals in healthcare and other fields.

Terveystalo is listed on Nasdaq Helsinki and has a strong Finnish ownership base. www.terveystalo.com

© 2026 GlobeNewswire (Europe)
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.